By Matt Richtel For two decades, researchers have used brain-imaging technology to try to identify how the structure and function of a person’s brain connects to a range of mental-health ailments, from anxiety and depression to suicidal tendencies. But a new paper, published Wednesday in Nature, calls into question whether much of this research is actually yielding valid findings. Many such studies, the paper’s authors found, tend to include fewer than two dozen participants, far shy of the number needed to generate reliable results. “You need thousands of individuals,” said Scott Marek, a psychiatric researcher at the Washington University School of Medicine in St. Louis and an author of the paper. He described the finding as a “gut punch” for the typical studies that use imaging to try to better understand mental health. Studies that use magnetic-resonance imaging technology commonly temper their conclusions with a cautionary statement noting the small sample size. But enlisting participants can be time-consuming and expensive, ranging from $600 to $2,000 an hour, said Dr. Nico Dosenbach, a neurologist at Washington University School of Medicine and another author on the paper. The median number of subjects in mental-health-related studies that use brain imaging is around 23, he added. But the Nature paper demonstrates that the data drawn from just two dozen subjects is generally insufficient to be reliable and can in fact yield “massively inflated” findings,” Dr. Dosenbach said. For their analysis, the researchers examined three of the largest studies using brain-imaging technology to reach conclusions about brain structure and mental health. All three studies are ongoing: the Human Connectome Project, which has 1,200 participants; the Adolescent Brain Cognitive Development, or A.B.C.D., study, with 12,000 participants; and the U.K. Biobank study, with 35,700 participants. The authors of the Nature paper looked at subsets of data within those three studies to determine whether smaller slices were misleading or “reproducible,” meaning that the findings could be considered scientifically valid. © 2022 The New York Times Company

Keyword: Brain imaging
Link ID: 28245 - Posted: 03.19.2022

Hannah Devlin Science corespondent Taking long naps could be a precursor of Alzheimer’s disease, according to a study that tracked the daytime sleeping habits of elderly people. The findings could help resolve the conflicting results of the effects of napping on cognition in older adults, with some previous studies highlighting the benefits of a siesta on mood, alertness and performance on mental tasks. The latest study suggests that an increase over time in naps was linked to a higher chance of developing mild cognitive impairment or Alzheimer’s. The scientists think it is more likely that excessive napping could be an early warning sign, rather than it causing mental decline. “It might be a signal of accelerated ageing,” said Dr Yue Leng, an assistant professor of psychiatry at the University of California San Francisco. “The main takeaway is if you didn’t used to take naps and you notice you’re starting to get more sleepy in the day, it might be a signal of declining cognitive health.” The scientists tracked more than 1,000 people, with an average age of 81, over several years. Each year, the participants wore a watch-like device to track mobility for up to 14 days. Each prolonged period of non-activity from 9am to 7pm was interpreted as a nap. The participants also underwent tests to evaluate cognition each year. At the start of the study 76% of participants had no cognitive impairment, 20% had mild cognitive impairment and 4% had Alzheimer’s disease. For participants who did not develop cognitive impairment, daily daytime napping increased by an average 11 minutes a year. The rate of increase doubled after a diagnosis of mild cognitive impairment to a total of 24 minutes and nearly tripled to a total of 68 minutes after a diagnosis of Alzheimer’s disease, according to the research published in the journal Alzheimer’s and dementia. © 2022 Guardian News & Media Limited

Keyword: Alzheimers; Sleep
Link ID: 28244 - Posted: 03.19.2022

Jon Hamilton About 1 in 7 people age 60 or older have a brain condition that may be an early sign of Alzheimer's disease. The condition, called mild cognitive impairment, occupies a gray zone between normal aging of the brain and dementia. And most people know almost nothing about it. A national survey found that 82% of Americans are unfamiliar with the condition or know very little about it. More than half thought the symptoms sounded like "normal aging," according to the survey, which was part of a special report released this week by the Alzheimer's Association. "Mild cognitive impairment is often confused with normal aging because it is very subtle," says Maria Carrillo, chief science officer of the Alzheimer's Association. Symptoms include "forgetting people's names, forgetting perhaps that you've said something already, forgetting a story, forgetting words," she says. The condition, which affects about 10 million people in the U.S., is defined as changes in memory and thinking that are noticeable to the affected person and those around them but not serious enough to interfere with the individual's everyday activities. That makes it tricky to diagnose, says Dr. Pierre Tariot, director of the Banner Alzheimer's Institute in Phoenix. So after talking to a patient, Tariot often asks if he can speak with the person's spouse or a close family member. A patient's wife, for example, might notice that her husband is still managing to keep his appointments, Tariot says, but then she adds: "But a year ago, he had it all locked and loaded in his brain. And now, unless he writes it down 12 times and then asks me to double-check, he's not going to get there." © 2022 npr

Keyword: Alzheimers; Learning & Memory
Link ID: 28243 - Posted: 03.19.2022

By Lisa Sanders, M.D. “You can’t see the ceiling, can you?” the man asked his 31-year-old wife. She grimaced, then shook her head. She was lying in bed looking toward the familiar shadows and shapes cast by the wintry morning sun. But she couldn’t see them. It was as if a dense white fog lay between her and those daily shifting patterns. Squinting didn’t help. Opening her eyes as wide as she could didn’t, either. All her life she had perfect vision. It was a secret source of pride. She’d never even seen an eye doctor. But that morning changed everything. She first noticed the trouble in her eyes six months earlier. She is a professional violinist and a teacher and that summer took her students to Italy to experience the sacred music and art. As she gazed up at the frescos decorating the ceiling of a favorite cathedral, a shimmering shape with jagged, irregular edges appeared out of nowhere. The points seemed to twinkle as the starlike image slowly enlarged. Inside the glittering outline, the colors were jumbled, like the crystals in a kaleidoscope. It was beautiful and terrifying. She dropped her head, closed her eyes and rubbed her aching neck. When she opened her eyes, the star burst, with its glimmering edges, was still there, distorting all that lay beyond it. It grew so large that it was almost all she could see. Then slowly it began to fade; after nearly a half-hour, the world started to resume its familiar look and shape. There had been similar, if less severe, experiences: Every now and then, when she would get up quickly after sitting or lying down, she would feel an intense pressure inside her head, and when it released, everything briefly looked faded and pale before returning to normal hues. These spells only lasted a few seconds and happened only a handful of times over the past few years. She wrote it off to fatigue or stress. After that day in Italy, those glistening star bursts appeared weekly, then daily. Stranger still, straight lines developed weird lumps and bumps when she looked at them out of the corner of her eye. Doorways, curbs and table edges seemed to waver, growing bulges and divots. When she looked at the object full on, it would obediently straighten out but resumed its aberration once it was on the sidelines again. © 2022 The New York Times Company

Keyword: Vision
Link ID: 28242 - Posted: 03.19.2022

Yasemin Saplakoglu Imagine that while you are enjoying your morning bowl of Cheerios, a spider drops from the ceiling and plops into the milk. Years later, you still can’t get near a bowl of cereal without feeling overcome with disgust. Researchers have now directly observed what happens inside a brain learning that kind of emotionally charged response. In a new study published in January in the Proceedings of the National Academy of Sciences, a team at the University of Southern California was able to visualize memories forming in the brains of laboratory fish, imaging them under the microscope as they bloomed in beautiful fluorescent greens. From earlier work, they had expected the brain to encode the memory by slightly tweaking its neural architecture. Instead, the researchers were surprised to find a major overhaul in the connections. What they saw reinforces the view that memory is a complex phenomenon involving a hodgepodge of encoding pathways. But it further suggests that the type of memory may be critical to how the brain chooses to encode it — a conclusion that may hint at why some kinds of deeply conditioned traumatic responses are so persistent, and so hard to unlearn. “It may be that what we’re looking at is the equivalent of a solid-state drive” in the brain, said co-author Scott Fraser, a quantitative biologist at USC. While the brain records some types of memories in a volatile, easily erasable form, fear-ridden memories may be stored more robustly, which could help to explain why years later, some people can recall a memory as if reliving it, he said. Memory has frequently been studied in the cortex, which covers the top of the mammalian brain, and in the hippocampus at the base. But it’s been examined less often in deeper structures such as the amygdala, the brain’s fear regulation center. The amygdala is particularly responsible for associative memories, an important class of emotionally charged memories that link disparate things — like that spider in your cereal. While this type of memory is very common, how it forms is not well understood, partly because it occurs in a relatively inaccessible area of the brain. All Rights Reserved © 2022

Keyword: Learning & Memory; Brain imaging
Link ID: 28241 - Posted: 03.16.2022

Rina Torchinsky Over the weekend, the model Hailey Bieber told her Instagram followers that she experienced stroke-like symptoms while at breakfast with her husband Thursday morning. Doctors found a small clot in her brain, she said, which caused "a small lack of oxygen." Bieber said on Instagram that her body passed the clot on its own, and she recovered within a few hours. Though Bieber recovered in her case, blood clots in the brain can lead to ischemic strokes, which make up a majority of all strokes. And among young people, stroke rates are on the rise. Here's what you need to know. Ischemic strokes happen when blood flow is blocked through an artery that delivers blood to the brain. These strokes account for the vast majority of all strokes, according to the Centers for Disease Control and Prevention. Transient ischemic attacks, which are sometimes called "mini-strokes," are different than ischemic strokes because these strokes block blood flow from the brain for a short period of time only — often, as short as five minutes. Like ischemic strokes, these strokes are also often caused by blood clots. Although these are short-lived, transient ischemic attacks warn of future strokes and are medical emergencies. More than a third of people who experience these do not receive treatment and have a major stroke within a year, according to the CDC. A hemorrhagic stroke is another type of stroke, which occurs when an artery in the brain leaks blood or ruptures. The leaked blood puts pressure on brain cells and damages them. High blood pressure and aneurysms can cause these strokes, the CDC says. Over the past 30 years, stroke incidence among adults 49 and younger has continued to increase in Southern states and the Midwest, the American Heart Association said in February. Rates have declined for those older than 75. © 2022 npr

Keyword: Stroke
Link ID: 28240 - Posted: 03.16.2022

By Linda Searing The more fit you are, the less likely you may be to develop Alzheimer’s disease — with those who are the most fit having a 33 percent lower risk for this dementia than the least fit, according to a report to be presented to the American Academy of Neurology at its annual meeting next month. FAQ: What to know about the omicron variant of the coronavirus D.C.-based researchers, from the Washington VA Medical Center and George Washington University, tested and tracked 649,605 veterans (average age 61) for nearly a decade. Based on their cardiorespiratory fitness, participants were divided into five categories, from lowest to highest fitness level. 10-minute exercising may slow progression to dementia for those with mild cognitive impairment The researchers found that, as fitness improved, people’s chances of developing the ailment decreased. Compared with the least-fit group, those slightly more fit had a 13 percent lower risk for Alzheimer’s; the middle group was 20 percent less likely to develop the disease; the next higher group was 26 percent less likely; with the odds reaching a 33 percent lower risk for those in the most-fit group. Alzheimer’s is the most common type of dementia. It is a progressive brain disorder that, over time, destroys memory and thinking skills and interferes with the ability to carry out daily tasks. About 6 million Americans 65 and older have Alzheimer’s. There are no proven ways to cure the disease. © 1996-2022 The Washington Post

Keyword: Alzheimers
Link ID: 28239 - Posted: 03.16.2022

By David Grimm In an unprecedented move, members of a confidential group that oversees animal research at the University of Washington (UW) have sued their own school to block the release of their names to an animal rights organization. People for the Ethical Treatment of Animals (PETA) has been trying to obtain this information for more than a year, charging that the makeup of the university’s Institutional Animal Care and Use Committee (IACUC) violates federal law. But the committee’s members—citing an uptick in animal rights activism at the school, including protests at the homes of individual scientists—say they fear PETA and other animal rights organizations will use their names to target them. “Animal rights groups have created a climate of fear at the university,” says the school’s IACUC chair, Jane Sullivan, who spearheaded the lawsuit. “I’m a huge fan of openness and transparency, but not when it threatens the safety of the members of my committee.” She and others fear PETA’s move is the beginning of a nationwide effort: The advocacy group also wants to name IACUC members at the University of Massachusetts (UMass) Amherst. Kathy Guillermo, a senior vice president at PETA, says her organization just wants UW's committee to comply with the law. “The IACUC is the last line of defense for animals in laboratories,” she says. But PETA suspects the university’s committee is so biased toward research interests that it’s not fulfilling its federal mandate. “The IACUC members’ supposed fear of releasing their names would appear to be more about hiding a flawed process than anything else.” Every U.S. institution that receives federal money for animal research must have an IACUC with five or more members, including scientists, veterinarians, and at least one nonscientist and one person unaffiliated with the institution. That makeup is supposed to ensure that animals are properly cared for and only necessary experiments take place, according to the U.S. National Institute of Health’s Office of Laboratory Animal Welfare (OLAW), which oversees these committees. Nonscientists can include ethicists and clergy members. © 2022 American Association for the Advancement of Science.

Keyword: Animal Rights
Link ID: 28238 - Posted: 03.16.2022

By Pam Belluck Covid-19 may cause greater loss of gray matter and tissue damage in the brain than naturally occurs in people who have not been infected with the virus, a large new study found. The study, published Monday in the journal Nature, is believed to be the first involving people who underwent brain scans both before they contracted Covid and months after. Neurological experts who were not involved in the research said it was valuable and unique, but they cautioned that the implications of the changes were unclear and did not necessarily suggest that people might have lasting damage or that the changes might profoundly affect thinking, memory or other functions. The study, involving people aged 51 to 81, found shrinkage and tissue damage primarily in brain areas related to sense of smell; some of those areas are also involved in other brain functions, the researchers said. “To me, this is pretty convincing evidence that something changes in brains of this overall group of people with Covid,” said Dr. Serena Spudich, chief of neurological infections and global neurology at the Yale School of Medicine, who was not involved in the study. But, she cautioned: “To make a conclusion that this has some long-term clinical implications for the patients I think is a stretch. We don’t want to scare the public and have them think, ‘Oh, this is proof that everyone’s going to have brain damage and not be able to function.’” The study involved 785 participants in UK Biobank, a repository of medical and other data from about half a million people in Britain. The participants each underwent two brain scans roughly three years apart, plus some basic cognitive testing. In between their two scans, 401 participants tested positive for the coronavirus, all infected between March 2020 and April 2021. The other 384 participants formed a control group because they had not been infected with the coronavirus and had similar characteristics to the infected patients in areas like age, sex, medical history and socioeconomic status. With normal aging, people lose a tiny fraction of gray matter each year. For example, in regions related to memory, the typical annual loss is between 0.2 percent and 0.3 percent, the researchers said. © 2022 The New York Times Company

Keyword: Chemical Senses (Smell & Taste); Learning & Memory
Link ID: 28237 - Posted: 03.11.2022

Alison Abbott Every two weeks, a nurse visits 43-year-old Marty Reiswig in Denver, Colorado, and injects him with an experimental drug called gantenerumab. Every month, Reiswig drives into town for a brain scan to make sure the drug has not caused any bleeds. And every year he flies to St Louis, Missouri, for four days of brain scans, spinal taps, blood analyses and exhaustive tests of his memory and reasoning capacity. Reiswig is fit and healthy and runs two local businesses. He goes through all of this because he has a rare genetic mutation that almost guarantees he will develop early-onset Alzheimer’s disease. He hopes that the international clinical trial he has been part of for nine years might prevent, or at least delay, the onset of symptoms that will otherwise arise in just a few years’ time. “I always do my best to give the researchers as much as I can — even if it turns out not to help me, it might help my children,” he says. The trial is one of several trying to understand whether treating the root cause of Alzheimer’s before symptoms start might be the best way to handle a disease that exacts such a large toll. The drugs under scrutiny are all antibodies that have been developed to target and clear amyloid-β proteins in the brain, which clog together into toxic masses called plaques (see ‘Antibodies against amyloid’). These drugs are of the same type as aducanumab, made by Biogen in Cambridge, Massachusetts, which was provisionally approved last year by the US Food and Drug Administration (FDA) for the treatment of mild Alzheimer’s, in large part owing to its ability to remove amyloid-β. And because such toxic proteins are a feature of several types of dementia, these antibody studies might also offer hints for how to treat the 55 million people around the world who have these conditions, says neurologist Paul Aisen at the University of Southern California in San Diego, who is a leader of the US Alzheimer’s Clinical Trials Consortium. Most dementias hit after 65 years of age; all have proved to be stubbornly incurable. Of more than 100 trials around the world, most are aiming to treat symptoms of the disease rather than its root cause. © 2022 Springer Nature Limited

Keyword: Alzheimers
Link ID: 28236 - Posted: 03.11.2022

By Christina Caron Q: Are there any proven treatments for low libido in women? “Proven” is a strong word — and one that makes scientists squeamish. But it is safe to say that there is “very strong evidence” for increasing sexual desire through certain types of psychological interventions like cognitive behavioral therapy and mindfulness meditation, said Lori A. Brotto, a psychologist and professor at the University of British Columbia in Vancouver and a renowned expert in women’s sexual health. When it comes to medications, however, it’s a different story. In recent years, two new medications for women with low libido have been approved by the U.S. Food and Drug Administration, “though their efficacy is marginally better than a placebo,” said Dr. Stacy Tessler Lindau, a gynecologist at the University of Chicago Medicine and the creator of WomanLab, a website about sexual health. These drugs, flibanserin (a pill) and bremelanotide (an injection that is self-administered about 40 minutes before sexual activity), were approved for the “very small subset of women” who are premenopausal, have low libidos and do not have any identifiable physical, mental or relationship problems, Dr. Lindau said. “They may have modest benefit, but they also come with side effects and cost,” she added. “So far, insurance coverage has been limited.” In the end, the most beneficial solution will depend on the reason you are experiencing low libido and why you consider your libido to be a problem. For older women, loss of estrogen during menopause is commonly associated with a change in libido because it can cause vaginal dryness and tightness that can make intercourse painful. Some women also find it more difficult to get aroused. And when menopause is accompanied by hot flashes and night sweats, that can make sex seem less appealing too. © 2022 The New York Times Company

Keyword: Sexual Behavior; Hormones & Behavior
Link ID: 28235 - Posted: 03.11.2022

By Veronique Greenwood Sharks are celebrated for their apparently ceaseless motion — a small handful of species such as great white sharks must even swim to breathe, keeping water washing over their gills. Still, all that moving doesn’t preclude sharks from having a rest. Sleep across the animal kingdom manifests itself in many peculiar ways, like the birds whose brains sleep one half at a time or the bats that spend almost every hour of their day snoozing. And in a paper published in Current Biology on Wednesday, researchers confirmed that the draughtsboard shark, a small nocturnal shark native to New Zealand, appears to be sleeping during periods of calm, reporting that their metabolism and posture change significantly during these bouts of repose. They do, however, in a creepy touch, keep their eyes open for a lot of it. Further research will be required to demonstrate that other kinds of sharks catch underwater z’s like the draughtsboard shark. But the new study supports the hypothesis that one reason organisms might have evolved sleep is as a tool for conserving energy. Draughtsboard sharks were identified last year as sleepers by this same group of researchers based in New Zealand and Australia. They watched captured sharks carefully in tanks and tested their responses to disturbances during their restful periods. (These sharks are not among those that swim to breathe; they hang out on the ocean floor and pump water over their gills.) The team found that it was more difficult to prompt the sharks into movement if they had been still for a long time, suggesting they were in fact sleeping. This time, said Craig Radford, a professor of marine science at the University of Auckland and an author of the new paper, the researchers were looking to compare the sharks’ metabolisms during these periods of calm, defined as being still for longer than five minutes, with when they were resting for shorter periods and when they were actively swimming. They used a specially built tank with instruments that let them monitor how much oxygen the sharks were using, a way to indirectly measure metabolism. Seven sharks each spent 24 hours in the tank, and the researchers found that these states were indeed quite different. © 2022 The New York Times Company

Keyword: Sleep; Evolution
Link ID: 28234 - Posted: 03.11.2022

Gabino Iglesias The Man Who Tasted Words is a deep dive into the world of our senses — one that explores the way they shape our reality and what happens when something malfunctions or functions differently. Despite the complicated science permeating the narrative and the plethora of medical explanations, the book is also part memoir. And because of the way the author, Dr. Guy Leschziner, treats his patients — and how he presents the ways their conditions affect their lives and those of the people around them — it is also a very humane, heartfelt book. We rely on vision, hearing, taste, smell, and touch to not only perceive the reality around us but also to help us navigate it by constantly processing stimuli, predicting what will happen based on previous experiences, and filling the gaps of everything we miss as we construct it. However, that truth, the "reality" we see, taste, hear, touch, and smell, isn't actually there; our brains, with the help of our nervous system continuously build it for us. But sometimes our brains or nervous system have a glitch, and that has affects reality. The Man Who Tasted Words carefully looks at — and tries to explain — some of the most bizarre glitches. Sponsor Message "What we believe to be a precise representation of the world around us is nothing more than an illusion, layer upon layer of processing of sensory information, and the interpretation of that information according to our expectations," states Leschziner. When one of those senses doesn't work correctly, that illusion morphs in ways that significantly impact the lives of those whose nervous systems or brain work differently. Paul, for example, is a man who feels no pain. While this sounds like a great "flaw" to have, Leschziner shows it's the opposite. Pain helps humans learn "to avoid sharp or hot objects." It teaches that certain things in our environment are potentially harmful, tells us when we've had an injury and makes us protect it, and even lets us know there's an infection in our body so we can go to the doctor. © 2022 npr

Keyword: Consciousness
Link ID: 28233 - Posted: 03.11.2022

By Roni Caryn Rabin Few of Covid-19’s peculiarities have piqued as much interest as anosmia, the abrupt loss of smell that has become a well-known hallmark of the disease. Covid patients lose this sense even without a stuffy nose; the loss can make food taste like cardboard and coffee smell noxious, occasionally persisting after other symptoms have resolved. Scientists are now beginning to unravel the biological mechanisms, which have been something of a mystery: The neurons that detect odors lack the receptors that the coronavirus uses to enter cells, prompting a long debate about whether they can be infected at all. Insights gleaned from new research could shed new light on how the coronavirus might affect other types of brain cells, leading to conditions like “brain fog,” and possibly help explain the biological mechanisms behind long Covid — symptoms that linger for weeks or months after the initial infection. The new work, along with earlier studies, settles the debate over whether the coronavirus infects the nerve cells that detect odors: It does not. But the virus does attack other supporting cells that line the nasal cavity, the researchers found. The infected cells shed virus and die, while immune cells flood the region to fight the virus. The subsequent inflammation wreaks havoc on smell receptors, proteins on the surface of the nerve cells in the nose that detect and transmit information about odors. The process alters the sophisticated organization of genes in those neurons, essentially short-circuiting them, the researchers reported. Their paper significantly advances the understanding of how cells critical to the sense of smell are affected by the virus, despite the fact that they are not directly infected, said Dr. Sandeep Robert Datta, an associate professor of neurobiology at Harvard Medical School, who was not involved in the study. © 2022 The New York Times Company

Keyword: Chemical Senses (Smell & Taste)
Link ID: 28232 - Posted: 03.05.2022

Linda Geddes Setting daily meat reduction goals and keeping an online diary of intake helped frequent meat eaters to halve their consumption in just over nine weeks, a trial has found. The trial, by researchers at the University of Oxford’s Livestock, Environment and People (Leap) programme, also found the routine was popular with participants, who felt it supported them to change their diet. Many people wish to reduce their meat consumption, whether for health or environmental reasons, or animal welfare concerns. Leap researchers wondered whether tapping into psychological principles employed by weight-loss apps, such as Noom, could help boost participants’ resolve. They developed an online platform called the Optimise meat tracker (standing for online programme to tackle individuals’ meat intake through self-regulation). Users log on and pick one meat reduction strategy from a list to focus on for that day, such as “try a new vegetarian recipe”, or “eat no processed meat”. The next morning they report whether they achieved this and record how much fish, poultry, red and processed meat they consumed. They receive weekly feedback on how they have done. The approach is based on self-regulation theory: the idea that people monitor and contextualise their own behaviour, reflect on it in relation to their goals, and try to modify it in response to feedback. “We know that people tend to underestimate the amount of meat they eat, the health and environmental impacts of their meat consumption; we also know that our meat-eating habits are strongly engrained. This process of self-regulation tries to tap into all of that,” said Dr Cristina Stewart at the University of Oxford, who led the research. © 2022 Guardian News & Media Limited

Keyword: Obesity
Link ID: 28231 - Posted: 03.05.2022

Brian Mann Nine state attorneys general have agreed to drop their objection to a deal granting immunity from opioid lawsuits to members of the Sackler family who own Purdue Pharma, the maker of OxyContin. In exchange, the family has agreed to increase the amount it pays from personal holdings from roughly $4.5 billion under a previous settlement to $6 billion. Washington state Attorney General Robert Ferguson described the terms of the new settlement as a victory. "Rather than join the majority of states in settlement, Washington chose to lead the fight against the Sacklers and Purdue," Ferguson said in a statement. "As a result, we won more than $100 million for Washington state to address the opioid epidemic, and more than $1 billion for states, cities and tribes across the country." The prior deal was overturned by a federal judge in Manhattan last December after some states and the Justice Department filed an appeal. States demanding more money from the Sacklers — California, Connecticut, Delaware, Maryland, New Hampshire, Oregon, Vermont and Washington — have among the highest overdose death rates in the country. In a statement, members of various branches of the Sackler family again denied any wrongdoing and described the settlement as one that will "allow very substantial additional resources to reach people and communities in need." "While the families have acted lawfully in all respects, they sincerely regret that OxyContin, a prescription medicine that continues to help people suffering from chronic pain, unexpectedly became part of an opioid crisis that has brought grief and loss to far too many families and communities." Critics, including many of the state attorneys general who approved this deal, have long accused members of the Sackler family of aggressively marketing opioids in ways that contributed to soaring rates of addiction and overdoses. © 2022 npr

Keyword: Drug Abuse
Link ID: 28230 - Posted: 03.05.2022

By Christa Hillstrom To hear more audio stories from publications like The New York Times, download Audm for iPhone or Android. In 2017, when Becky was about to turn 40, she woke up in the middle of the night and was startled by her reflection in the bathroom mirror. Her face, gaunt from weight loss, looked pale. A scar snaked under her chin from when her boyfriend punched her. Her nostrils were now asymmetrical from when he broke her nose. Smaller scars marked her eyebrows and her bottom lip, where a tooth once cut through. She always wore her hair in a bun to mask a bald spot; he had slammed her head against a door frame, and she had needed staples there. She could barely hear from one ear. Her chipped front tooth was harder to hide than the broken molars knocked loose during two decades of beatings. When she went shopping, she would hold items in her hands, assessing how much damage they would do to her body. She had stopped buying leather belts, the braided kind. She remembered getting some of her injuries. With others, the memories hung fuzzy and distant. They met in 1996, when she was a teenager with a new baby. She had already spent years raising her younger siblings when her own mother, who suffered from mental illness and was a survivor of domestic abuse, could not. The first time Becky remembers her boyfriend hurting her, about six months into their relationship, was when he was joking around: a tug on her hair that was surprisingly forceful. Underneath the laughing, something felt mean. And then the meanness got darker. From the beginning of their relationship, Becky’s boyfriend drew the reins tightly around their lives. She could never predict what would set him off. Some days, he attacked her for sleeping too late; others, for waking him up too early. He hit her when the house was too messy or if he wasn’t in the mood for the breakfast she made. Becky, who asked to be identified by a nickname for her safety, often showed up to work with bruises on her face, caked over with foundation, but her co-workers never said anything. © 2022 The New York Times Company

Keyword: Brain Injury/Concussion; Aggression
Link ID: 28229 - Posted: 03.02.2022

Researchers at the National Eye Institute (NEI) have discovered that power-producing organelles in the eye’s photoreceptor cells, called mitochondria, function as microlenses that help channel light to these cells’ outer segments where it’s converted into nerve signals. The discovery in ground squirrels provides a more precise picture of the retina’s optical properties and could help detect eye disease earlier. The findings, published today in Science Advances, also shed light on the evolution of vision. NEI is part of the National Institutes of Health. “We were surprised by this fascinating phenomenon that mitochondria appear to have a dual purpose: their well-established metabolic role producing energy, as well as this optical effect,” said the study’s lead investigator, Wei Li, Ph.D./B.M., who leads the NEI Retinal Neurophysiology Section. Using a modified confocal microscope, the researchers observed the optical properties of living cone mitochondria exposed to light. The path of light became concentrated with transmission from the inner to the outer segments of cone photoreceptors. Credit: John Ball, Ph.D., NEI The findings also address a long-standing mystery about the mammalian retina. Despite evolutionary pressure for light to be translated into signals and pass instantly from the retina to the brain, the trip is hardly direct. Once light reaches the retina, it must pass through multiple neural layers before reaching the outer segment of photoreceptors, where phototransduction (the conversion of light’s physical energy into cellular signals) occurs. Photoreceptors are long, tube-like structures divided into inner and outer segments. The last obstacle a photon must traverse before moving from the inner to the outer segment is an unusually dense bundle of mitochondria. Those bundles of mitochondria would seem to work against the process of vision either by scattering light or absorbing it. So, Li’s team set out to investigate their purpose by studying cone photoreceptors from the 13-lined ground squirrel.

Keyword: Vision
Link ID: 28228 - Posted: 03.02.2022

by Niko McCarty The ‘opto’ in optogenetics — the powerful method some autism researchers use to control neurons in mice and other animals — comes from the Greek optós, meaning visible. It’s a nod to the blue light used to switch on select neurons. A new technique can do the same, albeit with something invisible: sound. In a study published in Nature Communications this month, researchers engineered neurons in the motor cortex of mice to express an ultrasound-sensitive ion channel protein called hsTRPA1. They placed an ultrasound transducer near the animal’s skull and switched it on. The response? A flex of a muscle, a perceptible twitch. The approach, called sonogenetics, enables noninvasive control over any neural circuit that can be manipulated with optogenetics, an invasive method, says lead investigator Sreekanth Chalasani, associate professor in the Molecular Neurobiology Laboratory at the Salk Institute for Biological Studies in La Jolla, California. Spectrum spoke to Chalasani about his early experiments in Caenorhabditis elegans, lucky number 63 and how sonogenetics could one day have clinical applications. Spectrum: Our readers might be familiar with optogenetics, but I’m assuming sonogenetics is new for most people. Sreekanth Chalasani: Yeah. Well, the idea in sonogenetics is that we want to manipulate things noninvasively. Ultrasound can travel through bone and skin, into the body. We’ve been using it for decades. It’s safe. The question is: Can we leverage it to get in the body and control cells, like with optogenetics? S: Literally controlling cells with sound. SC: Right. In optogenetics, light triggers action potentials in cells that have a channelrhodopsin, or opsin, protein. In sonogenetics, we wanted a protein that would let us have that same level of cellular control. But finding that protein has been difficult. Lots of groups have been looking for these proteins, and we were fortunate to find one. © 2022 Simons Foundation

Keyword: Brain imaging
Link ID: 28227 - Posted: 03.02.2022

By Jan Hoffman For years, Dr. Xiulu Ruan was one of the nation’s top prescribers of quick-release fentanyl drugs. The medicines were approved only for severe breakthrough pain in cancer patients, but Dr. Ruan dispensed them almost exclusively for more common ailments: neck aches, back and joint pain. According to the Department of Justice, he and his partner wrote almost 300,000 prescriptions for controlled substances from 2011 to 2015, filled through the doctors’ own pharmacy in Mobile, Ala. Dr. Ruan often signed prescriptions without seeing patients, prosecutors said. Dr. Ruan has been serving a 21-year sentence in federal prison, convicted in 2017 for illegally prescribing opioids and related financial crimes. To collect millions of dollars in fines, the government seized houses, beach condos and bank accounts belonging to him and his business partner, as well as 23 luxury cars, such as Bentleys, Lamborghinis and Ferraris. On Tuesday, lawyers both for Dr. Ruan and for Dr. Shakeel Kahn, who is serving 25 years on charges related to pill mill clinics in Arizona and Wyoming will argue before the Supreme Court of the United States that the criminal standard the physicians faced is applied inconsistently among the federal circuits. In asking that the doctors’ convictions be overturned, they want the court to establish a uniform standard that permits doctors to raise a “good faith” defense. Juries could then consider whether doctors subjectively believed they were using their best medical judgment. The likelihood of these two doctors being set free is small, legal experts believe, but the court’s decision on the broader legal questions could have significant implications for the latitude doctors can take in prescribing potentially addictive painkillers and other restricted medications. The cases confront an uneasy relationship between law and medicine. In an era when overdose deaths are soaring, how should the law balance letting physicians exercise their best judgment with stopping egregious outliers? © 2022 The New York Times Company

Keyword: Drug Abuse; Pain & Touch
Link ID: 28226 - Posted: 03.02.2022